Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity.

Leo Sungwong ChoiIn Geun JoKu Suk KangJeong Ho ImJiyoung KimJinyoung KimJin Wook ChungSang-Ku Yoo

Published in: International journal of obesity (2005) (2020)

Our study demonstrates the key chemical components of glabridin pertinent to its weight loss effects and suggests HSG4112 as a promising novel drug candidate for the pharmacological treatment of obesity.

Keyphrases

weight loss
metabolic syndrome
insulin resistance
bariatric surgery
type diabetes
weight gain
adipose tissue
high throughput
combination therapy
body mass index
physical activity
gastric bypass
replacement therapy
glycemic control
obese patients